Navigation Links
Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP,,Rheumatoid Arthritis and Lymphoma

very well tolerated in the first dose group. To expedite patient recruitment, Rigel has added additional clinical sites that have significant experience in RA clinical trials. Rigel expects to receive results from the completed clinical trial in the second half of 2007.

Rigel today announced the enrollment of patients in a multi-center, Phase 2 clinical trial to evaluate the safety and efficacy of R788 for the treatment of patients with B-cell lymphoma. Approximately 80% of patients with non- Hodgkin's lymphoma have the B-cell variety, which is characterized by an over- expression of B-cell receptors and the proliferation of B-cells. Research has shown that R788 effectively interrupts the growth of B-cells and signaling proteins that contribute to the survival of these tumors.

The open label clinical trial is expected to enroll a total of approximately 60 patients at 10 major cancer treatment centers in the U.S. and will focus on refractory diffuse large, follicular and mantle B-cell lymphomas. The primary efficacy endpoint will be overall response rate according to standard criteria. Secondary efficacy, safety and pharmacodynamic endpoints, as well as the role of syk activation in predicting responses, will also be measured. Depending on enrollment, results of the clinical trial are expected in 2008.

R788 is a novel, oral syk kinase inhibitor that blocks the activation of mast cells, macrophages and B-cells that promote swelling, inflammatory responses and tissue damage. These activities derive from syk kinase's pivotal role in mediating immunoglobulin signaling inside cells. It is currently being evaluated in two Phase 2 studies with respect to RA and ITP, and enrollment in an additional Phase 2 clinical trial in B-cell lymphoma has commenced. Phase 1 trial results demonstrated that R788 was well tolerated and showed good pharmaceutical properties when administered both alone and, with respect to the treatment of patients with RA, in combinat
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Rigel to Present New Research Programs at AACR Meeting
2. Rigel Ubiquitin Ligase Program Identifies Molecules With Anti-HIV Activity
3. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
4. XTL Provides Update on Phase I Clinical Trial of XTL-2125
5. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
6. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
7. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
8. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
9. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
10. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
11. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
(Date:9/30/2014)... BURLINGTON, Mass. , Sept. 30, 2014  Decision ... (PV) devices in Brazil , ... and China (BRIC) will see ... techniques are increasingly favored over surgical procedures. Although revenues ... care resources, reimbursement challenges, prolonged device approval times and ...
(Date:9/30/2014)... September 30, 2014 ... the "Glycobiology/Glycomics Market by Product [Enzymes (Glycosyltransferase, Neuraminidase, ... and Reagents], Application (Immunology, Oncology) & by ... published by MarketsandMarkets, provides a detailed overview ... current market trends, and strategies impacting the ...
(Date:9/30/2014)... LEXINGTON, Ky. , Sept. 30, 2014 ... coherence tomography (OCT), offered a new look at the ... to alter how physicians understand and treat the disease, ... study, conducted at Baptist Health Lexington between September 2010 ... issue of the Journal of the American College ...
Breaking Medicine Technology:Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2
... , , VENLO, Netherlands , Feb. 2 QIAGEN N.V. ... financial results call. The Webcast will take place at 9:30 a.m. EST on ... President and Chief Executive Officer, and Roland Sackers, Chief Financial Officer. , ... QIAGEN,s fourth quarter and year-end 2009 financial , ...
... , JERUSALEM , Feb. ... ) announced today the availability of new resources to support ... to deliver Teva’s TEV-TROPIN® [somatropin (rDNA origin) for injection] brand ... due to inadequate secretion of normal endogenous growth hormone. The ...
Cached Medicine Technology:Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Fourth Quarter and Year-End 2009 Financial Results Call Set for February 9 2Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Fourth Quarter and Year-End 2009 Financial Results Call Set for February 9 3Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 2Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 3Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 4Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 5Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 6
(Date:10/1/2014)... Angeles, CA (PRWEB) October 01, 2014 ... power score of 3.1 out of 5, which ... users include food and beverage manufacturers, food service ... As a result of these users' diversity, demand ... As such, rising industrial production, consumer spending and ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 To help raise ... center , Cutler Integrative Medicine, is detailing several tips for ... , According to Dr. Cutler, women should start each ... time for yourself that will help ‘center’ yourself for the ... stress,” he says. , Other health and fitness tips ...
(Date:10/1/2014)... CO (PRWEB) October 01, 2014 Nearly ... after a Pueblo County District Court jury awarded him ... cancer at 61 years old. Casper had been ... , According to the Court Documents (District ... treated for BPH, a benign non-cancerous condition of his ...
(Date:9/30/2014)... be proactive about potential disease outbreaks like Ebola and ... an Editorial in the October issue of Australian ... Cheng from Monash University and Heath Kelly from the ... crises. , "Australia would do well to heed the ... co-ordinating a consistent and outward looking response," the authors ...
(Date:9/30/2014)... (HealthDay News) -- There,s no genetic evidence that high ... a new study says. Some previous research had ... people against type 2 diabetes, raising the possibility of ... sugar disease. In this study, British researchers investigated ... focusing on genes that control blood levels of vitamin ...
Breaking Medicine News(10 mins):Health News:Industrial Freezers Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Industrial Freezers Procurement Category Market Research Report Now Available from IBISWorld 3Health News:Industrial Freezers Procurement Category Market Research Report Now Available from IBISWorld 4Health News:In Recognition of National Women’s Health and Fitness Day, Cutler Integrative Medicine Details Tips for Living a Healthier and Happier Life 2Health News:Law Offices of D.R. Jones Client Wins 4.7 Million Dollar Verdict, Insurance Company Files Motion for a New Trial 2Health News:Law Offices of D.R. Jones Client Wins 4.7 Million Dollar Verdict, Insurance Company Files Motion for a New Trial 3Health News:Gene Study Finds No Proof Vitamin D Guards Against Type 2 Diabetes 2
... -- Racism is similar to trauma in how it ... United States, a new analysis finds. An examination ... black adults concluded that there are common responses to ... is expressed as physical pain), interpersonal sensitivity and anxiety. ...
... Nov. 24 (HealthDay News) -- Black Friday, the kickoff to ... as it is about getting good deals, according to a ... Friday adventure phenomenon, the more fun you,re likely to add ... Wake Forest University, said in a university news release. ...
... -- A 36-year-old husband and father of two children with ... world,s first artificial trachea made with stem cells. ... described the transplant surgery, which was performed in June ... the transplant, the authors of the report explained, the man ...
... By Jenifer Goodwin HealthDay Reporter , WEDNESDAY, ... Americans are hospitalized for adverse drug reactions yearly, and ... a new study finds. The four types of ... -- account for two-thirds of those drug-related emergency hospitalizations. ...
... that treats Type-2 diabetes has been shown to prevent ... the growth of breast cancer cells, according to a ... The research, led by pediatrics professor James Trosko ... biological evidence for previously reported epidemiological surveys that long-term ...
... , WEDNESDAY, Nov. 23 (HealthDay News) -- Preschoolers who ... are often prescribed inhaled steroid medication, and new research ... as-needed basis instead of every day. Respiratory ... and the treatment for some of these kids -- ...
Cached Medicine News:Health News:1st Artificial Windpipe Made With Stem Cells Seems Successful 2Health News:Four Common Meds Send Thousands of Seniors to Hospital: CDC 2Health News:Four Common Meds Send Thousands of Seniors to Hospital: CDC 3Health News:Diabetes drug shows promise in reducing risk of cancer 2Health News:Intermittent Steroid Use Called OK for Wheezing Preschoolers 2Health News:Intermittent Steroid Use Called OK for Wheezing Preschoolers 3
... The National Laboratory Training Network (NLTN) ... Association of Public Health Laboratories (APHL) and ... (CDC). NLTN provides cost-effective training in a ... resources, including a FREE Lending Library. Log ...
... The AAFP-PT Laboratory Proficiency Testing and ... programs are designed to assist POLs, clinics ... are designed to assure accuracy of patient ... regulatory requirements. Participation provides the opportunity to ...
An indirect immunofluorescence (IFA) antibody test for the detection and semiquantitation of anti-glomerular basement membrane (GBM) antibodies in human serum. Slide Detail: 6-well Monkey Kidney Subs...
An enzyme linked immunosorbant assay (ELISA) for the detection and quantitation of Rheumatoid Factor (RF) of IgM isotype in human serum....
Medicine Products: